Cian Healthcare Share Price

Overview 

Cian Healthcare Limited is a small‑cap pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical formulations, dietary supplements, and cosmeceutical products. Headquartered in Pune, Maharashtra, the company was incorporated in 2010 and has a manufacturing facility in Maharashtra. The Cian Healthcare share price on the NSE and BSE is a reflection of how market participants respond to a performance and broader business developments within its industry. It captures the company’s sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

Market sentiment around the Cian Healthcare stock price often mirrors shifts in demand for dietary supplements, cosmeceutical products, and generic formulations, raw material price volatility, and investor views on the prospects for small‑cap pharma firms. Factors such as the company’s ability to expand its product portfolio, manage regulatory compliance, and government policies on pharmaceutical manufacturing influence near‑term valuation and medium‑term earnings forecasts. All these factors must be closely monitored to have an idea about the Cian Healthcare share price movements. 

The Cian Healthcare live share price provides real‑time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Cian Healthcare live price helps observe short‑term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the Cian Healthcare share price today helps investors understand real‑time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short‑term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. The Cian Healthcare stock price remains sensitive to pharmaceutical sector trends. Cian Healthcare share price movements are closely tied to the healthcare industry’s performance. 

Cian Healthcare Limited Company Fundamentals 

A. Company Background

Cian Healthcare Limited was incorporated in 2010. The company’s registered office is located in Pune, Maharashtra, India. Cian Healthcare is engaged in the development, manufacturing, and marketing of pharmaceutical formulations, dietary supplements, and cosmeceutical products. The company has a manufacturing facility in Maharashtra and serves both domestic and export markets. It launched its initial public offering (IPO) on the BSE SME platform in 2019, listing its shares on the BSE. As a small‑cap entity, it operates in a competitive environment within the pharmaceutical and nutraceutical industries. The company is listed on the Bombay Stock Exchange (BSE) under the scrip code 542678. 

B. Product Lines 

• Pharmaceutical formulations (tablets, capsules, liquids) 

• Dietary supplements and nutraceutical products 

• Cosmeceutical products (skincare, hair care) 

• Healthcare and wellness products 

• Generic pharmaceutical preparations 

• Ayurvedic and herbal products 

C. Company Revenue Model 

• Primary revenue from manufacture and sale of pharmaceutical formulations, dietary supplements, and cosmeceutical products. 

• Volume‑driven revenue based on the quantity of products manufactured and sold to domestic and export markets. 

• Pricing determined by raw material costs and market demand, affecting overall revenue generation. 

• Revenue from the domestic pharmaceutical market, with some export exposure. 

• Focus on expanding product portfolio in high‑value nutraceutical and cosmeceutical segments. 

• Investment in research and development to develop new formulations. 

• Seasonal variations in demand for wellness products affecting revenue patterns. 

• Government policy changes on drug pricing and pharmaceutical regulations influencing revenue stability. 

D. Geographic Presence 

• Headquartered in Pune, Maharashtra, India. 

• Operations focused on the domestic Indian pharmaceutical and wellness market. 

• Export markets to select international countries. 

• Serves customers across multiple states within India. 

E. Key Milestones 

• 2010 – Company incorporated. 

• 2019 – Launched IPO on BSE SME platform. 

• Year – Commenced manufacturing operations. 

F. Industry Perspective

Cian Healthcare operates in the pharmaceutical and nutraceutical industry. Globally, the pharmaceutical market was valued at approximately USD 1.6 trillion in 2025 and is projected to reach USD 2.3 trillion by 2030, growing at a CAGR of 7.1%. India is the 3rd largest pharmaceutical market by volume and 14th by value. The Indian pharmaceutical market was valued at USD 50 billion in 2024 and is projected to reach USD 130 billion by 2030, growing at a CAGR of 15‑17%. The nutraceutical market in India is growing rapidly, valued at approximately USD 5‑7 billion and projected to grow at a CAGR of 18‑20% through 2030. Key drivers include rising health awareness, increasing disposable incomes, and the shift toward preventive healthcare. Challenges include intense competition from large pharmaceutical companies and unorganised players, volatile raw material prices, stringent regulatory compliance (GMP, ISO, WHO), and the need for continuous research and development. 

Cian Healthcare Limited Stock Market Presence: Listings & Index Representation 

Cian Healthcare is listed on the Bombay Stock Exchange (BSE) under the scrip code 542678. The company is not listed on the National Stock Exchange (NSE), though it is available on some trading platforms. The ISIN for the company is INE05BN01019. Its listing on the BSE ensures that the Cian Healthcare share price is accessible to a specific investor base. The company forms part of the BSE SmallCap index and is included in the BSE AllCap index. Being part of the BSE SmallCap index provides a benchmark for investors to compare the company’s performance against other small‑cap companies in the pharmaceutical sector. However, the company’s inclusion in major indices is limited, reflecting its small‑cap status. 

Cian Healthcare Limited Stock Performance and Share Price History 

The performance and share price history of Cian Healthcare Limited are influenced by a mix of operational, macroeconomic, and sectoral factors. A primary driver is the fluctuation in raw material prices, as any increase directly impacts the company’s input costs and margins, often leading to corrections in the Cian Healthcare share price. Government policies regarding drug pricing and pharmaceutical regulations also play a critical role. 

Another major factor is competition from both large pharmaceutical companies and unorganised players, which can alter long‑term demand projections and influence the Cian Healthcare share price. Quarterly financial results cause immediate swings in the Cian Healthcare stock price. Additionally, broader market trends and even seasonal demand for wellness products contribute to volatility. 

The 52‑week high of the stock is largely dictated by sentiment shifts. When the company reports strong operational performance, the Cian Healthcare share price tends to rally; conversely, any regulatory action can drive the Cian Healthcare share price down to a new low. The Cian Healthcare share price reached a 52‑week high of approximately ₹80‑90 and a 52‑week low of approximately ₹30‑40, indicating a wide trading range. The Cian Healthcare share price has a market capitalisation of approximately ₹25‑35 crore. 

The Cian Healthcare stock price has been particularly responsive to quarterly earnings releases. The Cian Healthcare stock price has shown a pattern of volatility in years when the company’s earnings were inconsistent. The Cian Healthcare stock price has shown a market capitalisation that has fluctuated between approximately ₹25 crore and ₹35 crore in recent quarters. 

The Cian Healthcare share price reached its 52‑week high before declining, reflecting the volatility inherent in the small‑cap pharma space. The Cian Healthcare share price has shown a year‑to‑date return that has been moderate as of early 2026. Comprehending these patterns in the Cian Healthcare share price is instrumental for investors seeking to contextualise long‑term performance trends, as the Cian Healthcare stock price movements illustrate how pharmaceutical industry fundamentals, raw material cycles, and investor expectations converge in market pricing. 

Cian Healthcare Limited Investor Relevance and Role in Portfolio 

Cian Healthcare holds a limited position for portfolio investors who seek exposure to the pharmaceutical and nutraceutical sector. The company’s operations in pharmaceutical formulations and dietary supplements align it with investment strategies that value healthcare and wellness themes. The Cian Healthcare share price often mirrors how these themes resonate with investor portfolios. 

Institutional stakeholders play a role in Cian Healthcare’s ownership profile. Promoter holding details are not consistently reported. Mutual funds hold 0% stake. Foreign Institutional Investors (FII) hold 0%, Domestic Institutional Investors (DII) hold 0%, and Insurance companies hold 0%. The retail public holds the majority stake. 

Based on data, Cian Healthcare exhibits varying levels of beta and volatility across different time horizons. Based on data, the long‑term beta of Cian Healthcare is not consistently reported. Based on data, the weekly volatility has been reported as moderate. The Cian Healthcare stock price has shown periods of heightened responsiveness to sector‑specific news regarding pharmaceutical regulations and raw material prices. The Cian Healthcare share price’s beta reflects that the company’s small‑cap status makes it subject to company‑specific factors rather than broad market trends. 

Cian Healthcare Limited Sectoral Relevance and Peer Positioning 

The sector relevance of Cian Healthcare is anchored in its role within the broader Indian pharmaceutical and nutraceutical industry. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr. Reddy’s Laboratories Ltd, and other small‑cap nutraceutical companies. In the dietary supplement segment, peers include other nutraceutical manufacturers. 

In valuation terms, factors like the Cian Healthcare P/E ratio have shown variations over different periods. The current P/E ratio is not consistently reported. Cian Healthcare earnings have been modest, with the company reporting revenue growth in certain periods. The Cian Healthcare EPS has been low but positive in some periods. The Cian Healthcare market cap has fluctuated between approximately ₹25 crore and ₹35 crore over the past few years, in line with investor perceptions of the company’s growth potential in the pharmaceutical market. 

The Cian Healthcare earnings over the past few years have been characterised by periods of modest profitability. The Cian Healthcare share price has been influenced by these valuation metrics. The Cian Healthcare stock price continues to be evaluated in the context of its earnings potential and product pipeline. 

Summary 

Cian Healthcare is a small‑cap pharmaceutical and nutraceutical company listed on the BSE, where the Cian Healthcare share price reflects raw material price fluctuations, healthcare demand cycles, and small‑cap market sentiment within the pharma sector. Its inclusion in the BSE SmallCap index supports limited visibility, while investor interest is shaped by earnings trends and broader healthcare and wellness themes. Within the sector, the company’s competitive context and earnings dynamics provide perspective on its role in India’s nutraceutical industry.